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Background and objective: Today osteoporosis is the most common bone disease and 
important public health problem in all developed countries. The objective of this study was to estimate 
the costs associated with the management and treatment of osteoporosis in order to assess the 
economic burden in Italy for 2017, in terms of direct medical costs and social security costs. 
Methods: A Cost of Illness model was developed to estimate the average cost per year 
sustained by the NHS (National Health Service) and Social Security System in Italy. A Systematic 
Literature Review was performed to obtain epidemiological, direct and indirect costs parameters 
where available. Hospitalization costs were calculated considering the administrative database of 
Hospitalization available in Italy between 2008-2016. Patients were enrolled in the analysis if they 
report the subsequent inclusion criteria: age ≥ 45 years and presence of osteoporosis in primary or 
secondary diagnosis (ICD9-CM 733.0) and/or presence of a major fracture in primary or secondary 
diagnosis (excluding road accidents) in the following locations: spine (codes ICD9-CM: 805;806), 
femur (codes ICD9-CM: 820; 821), radiusm and ulna (codes ICD9-CM: 813.4; 813.5), humerus 
(codes ICD9-CM: 812.0-812.5), pelvis (code ICD9-CM: 808), tibia and fibula (codes ICD9-CM: 
823), ankle (code ICD9: 824) and ribs (codes ICD9-CM: 807.0; 807.1).. Costs were estimated 
considering the DRG (Diagnosis-related group) national tariff associated with each hospitalisation. 
Finally, the administrative databases of the National Social Security Institute (INPS) (2009-2015) 
were analysed for the estimate the pension and disability costs from the social perspective. 
Results: The model estimated an average annual economic burden of osteoporosis in Italy 
of € 2.2 billion. Of this cost, 80 % (€ 1.8 billion) was associated to hospitalizations, 16% (€ 0.35 
billion) for pharmacological treatments, 3% (€ 0.07 billion) to ambulatory visits, and 1% (€ 0.01 
billion) to social security costs. The average yearly cost per patient was equal to € 8,691(€ 8,591 for 
hospitalizations). Analysing severe patients, hospitalization costs increase to € 12,336 (+44% if 
compared to general osteoporosis patients). 
Conclusions: The analysis showed that osteoporosis represents one of the main health 
problems in Italy and the ability to maintain patients in a non-severe health state could decrease the 









• Overall, the economic burden associated to the osteoporosis patients in Italy was equal to € 
2.2 billion from the NHS and social security system perspective; 
• 81% (€ 1.8 billion) of the total economic burden was associated to hospitalization costs (63% 
related to hospitalizations due to fractures, 37% to hospitalizations due to other causes), 16% 
(€ 351 million) to pharmacological treatments cost, 3% (€ 71 million) to ambulatory visits 
and 1% (€ 13 million) to social security cost; 
• the average annual hospitalization cost per patient with severe osteoporosis (subjects aged ≥ 
45 years with osteoporosis in primary or secondary diagnosis and with a fracture, the subjects 
aged ≥ 45 years with two fractures and those aged ≥ 45 years with three or more fractures.) 
was € 12,336 (+XX% if compared to non severe patients € 8,591) 
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1. Introduction 
Osteoporosis is a systemic disease characterized by low bone mass and by qualitative 
alterations of macro- and micro-architecture of the skeletal tissue, such as to increase bone fragility 
and, therefore, the risk of fracture even for low/medium energy traumas [1].   
The most frequent osteoporotic fractures are those of the wrist, humerus, ribs, pelvis, spine 
column and femur. These fractures can cause complex disabilities, morbidity, reduced quality of life 
and functional limitation. Moreover, spine and hip fractures increase the relative risk of mortality [2]. 
Although osteoporosis has been historically considered a disease mainly affecting post-
menopausal women, in recent years it has been shown that fragility fractures are a statistically 
significant event in men [3]. Conventionally, this disease occurs into two distinct forms: 
1. Primary osteoporosis: occurring after menopause (type I osteoporosis) or with ageing (type 
II osteoporosis). 
2. Secondary osteoporosis: due to the presence of other clinical conditions (endocrine-metabolic 
diseases, myelo-and lymphoproliferative diseases, conditions associated with intestinal 
malabsorption, rheumatic diseases, kidney diseases, organ transplantation) or to the taking of 
certain medication in the medium-long term (glucocorticoids, aromatase inhibitors).   
The term idiopathic osteoporosis, on the other hand, identifies a form of osteoporosis for which 
there is no clear cause that can explain the onset of the disease [4-6]. The incidence and prevalence 
of osteoporotic fractures increase exponentially with age [7], generating significant social and 
economic costs. Certainly, gathering exact information and data on welfare flows and related 
expenditure is a starting point for the improvement of healthcare programmes and the development 
of cost containment policies. 
In Italy, during the last decade, the demographic structure of the population increases the 
number of osteoporosis patients due to the ageing population. It was estimated that more than the half 
of postmenopausal women aged 50 and older in Italy have osteoporosis on the basis of the most recent 
criteria [8]. The increasing level of osteoporosis disease represents one of the main in issue not only 
from the NHS perspective but also from a social perspective. In Italy, information on the burden of 
osteoporosis across age groups, sex, and fracture sites is also lacking. 
The objective of this study was to develop a Cost of illness (CoI) model able to estimate the 
costs associated with the management and treatment of osteoporosis in Italy in one year, from the 




2.1 Study design 
The CoI model was developed starting from the prevailing patients. The reference year for the 
analysis was 2017.  
The perspective used was that of the NHS and the national social security system. Therefore, 
direct costs (the costs directly related to the diagnosis and treatment of the disease) and social security 
costs (the costs related to disability allowances and pensions paid, under certain conditions, to 
patients) respectively were estimated. 
Epidemiological and cost data were obtained by conducting a systematic review of the literature 
(SRL) and by consulting the administrative database of hospital discharge records (HDR) and the 
database of the National Social Security Institute (INPS). 
2.2 Systematic literature review 
In order to find the national epidemiological and cost data available from the literature, in 
January 2019, a SLR was conducted, using different search engines (PubMed, EpiCentro) and 
consulting Italian health economics journals (Farmacoeconomia e Percorsi Terapeutici, 
PharmacoEconomics Italian Research Articles, Global and Regional Health Technology 
Assessment). Articles relating to the past 5 years have been reviewed. 
In accordance with the recommended guidelines for the systematic analysis of scientific 
literature [9], the systematic process was divided into 4 stages: identification, screening, eligibility 
and inclusion. 
In the first stage (identification), the search terms to be used to extract articles from each single 
consulted electronic database were identified: 
• Pubmed: 
- Cost items: 
(economic evaluation[Title/Abstract] OR cost[Title/Abstract] OR 
burden[Title/Abstract] OR economic impact[Title/Abstract]) AND 
(osteoporosis[Title/Abstract] OR BMD[Title/Abstract] OR 
Osteoarthritis[Title/Abstract] OR OSTC[Title/Abstract] OR “Osteoporosis”[Mesh])  
- Epidemiological articles: 
(epidemiology[Title/Abstract] OR epidemiology[MeSH Terms] OR 
prevalence[MeSH Terms]) AND osteoporosis[MeSH Terms] 
• Pharmaeconomics and therapeutic pathways: COST + OSTEOPOROSIS 
• Google scholar: EPIDEMIOLOGY OR PREVALENCE + COST OR BURDEN + 
OSTEOPOROSIS 
• EPICENTRO: COST + EPIDEMIOLOGY + OSTEOPOROSIS 
• Pharmacoeconomics Italian Research Articles: EPIDEMIOLOGY OR PREVALENCE + 
COST OR BURDEN + OSTEOPOROSIS 
• Global & Regional Health Technology Assessment: EPIDEMIOLOGY OR PREVALENCE 
+ COST OR BURDEN + OSTEOPOROSIS 
 
This first stage identified 232 articles through PubMed and 238 articles through the other 
electronic databases mentioned above. 
 
In the second stage (screening), duplicates were removed from the total number of identified 
articles. This process is necessary when the SLR is carried out on more than one electronic database. 
In the third stage (eligibility), two researchers independently reviewed the studies, using the 
title, abstract or extended text, in order to include (fourth stage) only the studies meeting at least one 
of the following inclusion criteria: 
• nationwide studies containing data on the direct costs of the disease, examined from 
the perspective of the NHS, and expressed in monetary values by hospital groups 
related to the disease (DRG) and outpatient rates; 
• nationwide observational studies on epidemiological and/or cost data for osteoporosis; 
• national or international studies reporting significant nationwide data for osteoporosis. 
At the end of the review process, 4 articles were included in the analysis (Figure 1).  
Figure 1 PRISMA Flow chart 
  
2.3 Querying administrative databases 
In order to estimate the hospitalization costs related to osteoporosis disease, it was developed 
an analysis on the administrative database of the Hospital Discharge Records (HDR) for the period 
2008-2016.HDR collects all hospitalizations events occurred in all public and private institutes of 
Italy. The discharge records include the patient’s demographic (gender, age, education, residence) 
and clinical information, the diagnosis and the main and secondary procedures (5 fields) as set out in 
the International Classification of Diseases (ICD-9-CM). Costs were estimated considering the DRG 
(Diagnosis-related group) national tariff associated with each hospitalisation 
Through the analysis conducted on the HDR, it was possible to select the number of subjects 
with osteoporosis, according to the following inclusion criteria: age ≥ 45 years and presence of 
osteoporosis in primary or secondary diagnosis (ICD9-CM 733.0) and/or presence of a major fracture 
in primary or secondary diagnosis (excluding road accidents) in the following locations: spine (codes 
ICD9-CM: 805;806), femur (codes ICD9-CM: 820; 821), radius and ulna (codes ICD9-CM: 813.4; 
813.5), humerus (codes ICD9-CM: 812.0-812.5), pelvis (code ICD9-CM: 808), tibia and fibula 
(codes ICD9-CM: 823), ankle (code ICD9: 824) and ribs (codes ICD9-CM: 807.0; 807.1).  
The subjects were broken down into three age groups (< 60, 60-74, ≥ 75). The national average 
annual number of admissions and the average annual expenditure for subjects with osteoporosis were 
obtained as the average value of the number of admissions and the expenditure estimated for the nine 
years being analysed. 
A further objective of this study was to focus on the costs related to patients with severe 
osteoporosis, where severe means the presence of a previous fracture in the patient with osteoporosis. 
Using the HDR information database analysed for the period 2008-2016, it was possible to select all 
the subjects aged ≥ 45 years with osteoporosis in primary or secondary diagnosis and with a fracture, 
the subjects aged ≥ 45 years with two fractures and those aged ≥ 45 years with three or more fractures.  
The estimate of social security costs was calculated by consulting the databases of the National 
Social Security Institute (INPS) for the period 2009-2015. The national social security system in Italy 
aims to protect workers and family members in the event of (partial or total) loss of working capacity 
due to illness. This protection function is carried out through the payment of Disability Benefits (DB) 
or Incapacity Pension (IP). All categories of workers registered with the Italian National Social 
Security Institute (INPS) have the right to receive DB or IP in case of an accident or illness and after 
five years of welfare insurance contributions [10]. 
The DB is a financial benefit for all categories of workers registered with INPS (mainly private 
sector employees and self-employed workers), with five years of social security contributions, and 
with workability reduced to less than one-third due to physical or mental illness. It is necessary to 
apply for it, and if the medical board approves, it is not required to cease work. The allowance is 
recognized for a period of three years and is confirmable for periods of the same duration. After three 
consecutive awards, it is automatically confirmed. This type of allowance is funded and paid for 
thirteen months by INPS. The IP is a financial benefit for all categories of workers registered with 
INPS to which has been recognized an absolute and permanent inability to work. Also in this case, 
five years of social welfare contributions, and a specific application are necessary. Retirement from 
work is required. This type of pension is funded and paid by INPS and it is paid for thirteen months, 
too [10]. 
All patients with a recognised Disabilty Benefits (DB) - paid to individuals with a degree of 
disability between 67% and 99% - or an Incapacity Pension (IP) - paid to individuals with a degree 
of disability equal to 100% - were identified considering the subjects diagnosed with osteoporosis 
and/or the subjects aged > 60 years with a fracture, in primary or secondary diagnosis; these patients 
were subsequently broken down according to the presence or absence of comorbidity in the secondary 
diagnosis. As in the case of hospitalizations, the average annual number of accepted applications and 
the related average annual expenditure were obtained as the average of the accepted applications and 
the estimated expenditure in the seven years being analysed. 
A variability measure of the total economic burden was estimated considering: the minimum 
and maximum parameter reported in table 1 for drug and specialistic visits, the minimum and 
maximum annual hospitalization cost registered between 2008 – 2016, the minimum and maximum 
annual social security cost between 2009 – 2015. 
  
3. Results 
3.1 Estimate of the population with osteoporosis 
According to the information found in the literature [11, 12], the average age of the patients 
suffering from osteoporosis in Italy is 50 years, specifically 45 years for women and 55 years for 
men. 
With regard to the prevalence data available in the literature, an average value for women 
(base case) of 20.95% (min=18.50%; max=23.40%) [11, 12], and an average value for males of 
8.45% (min=6.90% [11]; max=10% [12]) have been estimated. 
Applying the average prevalence values obtained from the literature to the population living 
in Italy as of 1 January 2017 aged ≥ 45 years (16,701,772 women and 9,669,652  men)  [13], the 
number of people suffering from osteoporosis in Italy in 2017 was 4,316,107  subjects (3,499,021  
women and 817,086  men). 
The prevalence values clearly show that the majority of individuals with osteoporosis are 
female (81%). 
The consequences of osteoporosis are measurable, among other elements, in the number of 
fractures that the patient undergoes due to the microarchitectural deterioration of the bone tissue 
caused by the disease and that exposes the patient to a greater risk of fracture. 
Not all the patients suffering from osteoporosis actually experience a fracture. The average 
annual number of fractures identified analysing the national HDR administrative database for the 
period 2008-2016 was equal to 215,302 (from an estimated number equal to 207,884 patients). With 
reference to the location of the fracture, 53.9% (115,972) of the total fractures were hip fractures, 
10.3% (22,120) humerus fractures, 9.1% (19,575) spinal column fractures, 8.3% (17,785) ribs 
fractures, 6.3% (13,593) fractures of the radius or ulna, 5% (10,764) pelvis fractures, 4.1% (8,867) 
ankle fractures and 3.1% (6,626) fibula or tibia fractures. 
However, the number of fractures obtained is underestimated. With the data at our disposal, 
it has not been possible to trace the patients who are not hospitalized, due to the fact that they might 
have been treated only in the emergency department or they might not have been treated at all in an 
emergency department, as it often happens with spine fractures. 
The epidemiological parameters identified through to the systematic review process and the 
analysis of the HDR database are reported in table 1. 
Table 1 – Epidemiological parameters 
 
EPIDEMIOLOGICAL 
PARAMETERS BASE CASE MIN MAX 
OSTEOPOROTIC 
POPULATION SOURCE NOTES 
Women population 
aged 45+ resident in 
Italy at 1st January 
2017 
16,701,772 - - _ [13] - 
Men population aged 
55+ resident in Italy at 
1st January 2017 




20.95% 18.50% 23.40% 3,499,021 [11, 12]  Age: 40+ ; 50+ 
Prevalence of 
osteoporosis in men 8.45% 6.90% 10% 817,086 [11, 12]  Age: 50+ ; 60+ 
Total osteoporotic 
population in Italy in 
2017 
- - - 4,316,107 - - 
Average annual 
number of fractures 215,302 _ _ - - - 
 
3.2 Estimated costs associated with patients with osteoporosis 
The direct health costs considered in the analysis were referred to the cost of drugs, 
ambulatory visits and hospitalizations. 
The cost of drugs and ambulatory visits has been obtained through the average cost estimates 
emerging from the literature [12, 14, 15]. These average values have been subsequently re-valued to 
2017 [16]. 
By applying the average costs per patient to the total number of patients with osteoporosis in 
Italy in 2017, it was possible to obtain a total cost for drugs and ambulatory visits of € 350,793,740 
and € 70,697,830  respectively.   
Hospitalization costs were estimated considering the expenditure associated with 
hospitalizations due to fractures and other causes (See Appendix for detail of the main DRGs 
registered) of the patients selected by the HDR database (Table 2). 
Table 2 – Average number of subjects with osteoporosis and hospitalizations due to fractures or other 
causes – HDR database analysis 2008-2016 
 
Age groups Subjects with osteoporosis 
Hospitalizations 







due to fractures) 
Average 
hospitalizations 
per patient (other 
hospitalizations) 
<60 4,245 392 7,627 0.09 1.80 
60-74 62,685 58,195 52,558 0.93 0.84 
75+ 140,953 145,374 110,750 1.03 0.79 
Total 207,884 203,961 170,935 0.98 0.82 
 
The average annual cost of hospitalizations, obtained as the average value of the estimated 
costs for each year of analysis (2008-2016), was equal to € 1,785,874,284. 63% of this cost (€ 
1,120,328,011) was attributable to hospitalizations for fractures, while the remaining 37% (€ 
665,546,274) for causes other than fractures. The average annual cost per patient with osteoporosis 
was € 8,591. 
The highest average annual cost of hospitalization per patient was recorded for patients aged 
over 75 years (€ 9,050), followed by the average cost per patient in the 60-74 age group (€ 7,734) and 
the average cost per patient aged under 60 years (€ 5,991) (Figure 2). 
Figure 2 – Hospitalization expense by age group 
 
 
The average annual cost per patient with osteoporosis in terms of direct costs was € 8,688; 
about 81% of this average cost was attributable to hospitalizations (€ 8,591), while about 16% and 
3% to pharmacological treatment and ambulatory visits respectively. 
The identification of the applications accepted by DB and IP through the ICD9 codes, according 
to the inclusion criteria described above, has identified an average annual number of beneficiaries 
equal to 1,528 (1,422 beneficiaries of DB and 106 beneficiaries of IP) and an average annual cost of 
€ 13,377,798 (Table 3), estimated for the period 2009-2015. 90% of this average cost was 
characterized by the payment of DB (Table 4). In particular, 83% (€ 11,155,565) of the estimated 
national average annual cost was characterized by social security costs related to osteoporosis-and/or 
fracture-diagnosed patients in primary or secondary diagnosis, presenting other diseases in primary 
or secondary diagnosis. The remaining 17% (€ 2,222,233) was due to costs related to patients with 
osteoporosis-and/or fracture in primary or secondary diagnosis with no other comorbidity. 
Table 3 – Social security costs and number of beneficiaries (Italy 2009 – 2015) 
 
  Total costs  2009-2015 Average annual beneficiaries Average annual costs 
DB € 84,052,611 1,422 € 12,007,516 
IP € 9,591,974 106 € 1,370,282 
Total € 93,644,585 1,528 € 13,377,798 
DB = Disability Benefits; IP = Incapacity Pension 
 
3.3  2017 Italy CoI  
The model estimated a total cost for osteoporosis in Italy in 2017 of about € 2.2 billion, of 
which 99.4% was characterized by direct costs. Table 4 reports the estimated national annual average, 
minimum and maximum (considering the variability registered in the literature and from the 
administrative databases) annual costs, and the percentage distribution for each cost item considered 
in the analysis. 
 
Table 4 – 2017 CoI of osteoporosis in Italy 
  Average annual cost in Italy Min Max Percentage 
Pharmacological treatment € 350,793,740 € 344,790,997 € 453,386,587 15.93% 
Ambulatory visits € 70,697,830 € 69,488,056 € 91,374,058 3.21% 
Hospitalizations € 1,785,874,284 € 1,651,198,711 € 1,898,846,999 80.26% 
Social security system € 13,377,798 € 9,981,115 € 18,249,383 0.60% 
Total Cost € 2,220,743,653 € 2,075,458,879 € 2,461,857,027 100% 
  
4. Focus on patients with severe osteoporosis 
The average annual number of hospitalizations due to fractures in patients with severe 
osteoporosis was 33,150, while the average annual number of hospitalizations for reasons other than 
fracture was 16,131. The average annual cost associated with admissions of patients with severe 
osteoporosis was € 223,257,024, of which 70% (€ 156,389,721) was attributable to hospitalizations 
for fractures and 30% (€ 66,867,303) to hospitalizations for other causes. Figure 4 reports the average 
annual costs associated with hospitalizations for fractures and hospitalizations for other causes 
estimated for each year of analysis. 
The average annual cost associated with hospitalizations for patients with severe osteoporosis 
was € 12,336, thus higher (+ € 3,745) than that estimated for a patient with non-severe osteoporosis 
(€ 8,591). 
 







Today osteoporosis is the most common bone disease and represent a socially relevant public 
health problem in all developed countries [8]. However, there are currently no studies in the literature 
that have attempted to quantify the cost of osteoporosis, going beyond the quantification of costs 
directly related to the diagnosis and treatment of the disease. As a result, although this analysis (as it 
will be shown in the presentation of the limitations of the study) most likely tends to underestimate 
the overall economic burden of the disease, it estimates the costs from a broader perspective than in 
previous studies [14]. 
In addition to the information found in the literature on drug costs and ambulatory visits, this 
analysis has allowed to include the costs of hospitalizations, estimated thanks to the consultation of 
the national HDR database, and social security costs, obtained through the administrative database of 
the National Social Security Institute. 
In fact, although social security costs represent a very small part of the total cost quantified in 
this study, they have increased over the years (especially with regard to Ordinary Disability 
Allowances). 
The analysis resulted in a total disease cost of more than € 2 billion in 2017, about 99% of 
which is made up of direct health costs. Among the items considered (pharmacological treatment, 
ambulatory visits and hospitalizations), the cost of hospitalizations, amounting to about €1.8 billion 
(approximately 80% of the total direct health costs), was the cost weighing more on the total. This is 
most likely due to the longer average length of hospitalization time of a patient with osteoporosis than 
that of other chronic diseases - fractures (especially femoral/hip ones) require longer rehabilitation 
time - and to the costs for prostheses, which are frequent for the treatment of hip fractures. 
The costs associated with pharmacological treatments (basically aimed at reducing the risk of 
fractures) and ambulatory visits amounted to about € 351 million (approximately 16% of the total) 
and about € 71 million (about 3% of the total) respectively. 
Social security costs, which accounted for only 0.6% of the total costs associated with 
osteoporosis, amounted to about € 13 million, of which approximately 89% was characterised by 
costs relating to the payment of  DB.  
The study is not without limitations. First of all, the costs of fragility fractures that do not 
involve hospitalization have not been considered because they are managed only in the emergency 
department or they are not treated at all, as it often happens for spinal fractures. Secondly, some cost 
items associated with the disease, such as indirect costs for patients or caregivers (i.e. costs related to 
the loss of productivity at work due to the disease) have not been estimated. Indeed, the management 
and drug treatment didn’t remain the same over the 5 years considered in the analysis. However, these 
costs may not represent a high share of the total cost because osteoporosis mainly affects aged people 
and therefore no longer in working age (2% of the HDR analysis had an age lower than 60 years). 
Finally, the databases consulted are administrative and not clinical. Therefore, it has not been 
possible to carry out a breakdown of patients according to the disease severity, as these databases do 
not take into account the risk factors that may affect hospitalizations.  
Considering the above limitations, we can, therefore, state that the analysis conducted tends 
to underestimate the overall economic burden of osteoporosis. 
6. Conclusions 
This Cost of Illness (CoI) study was conducted in order to quantify the overall burden of the 
patients suffering from osteoporosis in Italy from the perspective of the NHS and that of the social 
security system. This cost was equal to € 2,220,743,653 in 2017, demonstrating that osteoporosis 
represents a significant health problem because it generates a high economic burden, especially in 
terms of hospitalization. In particular, most of the estimated costs were due to hospitalizations 
because an osteoporotic patient who experiences a bone fracture, especially a hip fracture, encounters 
medium-long hospitalization time due, above all, to the time of post-operative rehabilitation. 
Moreover, it was shown that hospitalization costs increase in patients with severe osteoporosis (+ 







Tabella 1 - DRGs considered 
DRG Description % 
249 AFTERCARE, MUSCULOSKELETAL SYSTEM & CONNECTIVE TISSUE 9,4 
127 HEART FAILURE & SHOCK 4,8 
087 PULMONARY EDEMA & RESPIRATORY FAILURE 3,4 
256 OTHER MUSCULOSKELETAL SYSTEM & CONNECTIVE TISSUE DIAGNOSIS 3,4 
245 BONE DISEASES & SPECIFIC ARTHROPATHIES WITHOUT COMPLICATIONS, COMORBIDITIES 2,2 
012 DEGENERATIVE NERVOUS SYSTEM DISORDERS 2,1 
088 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 1,8 
089 SIMPLE PNEUMONIA & PLEURISY AGE >17 WITH COMPLICATIONS, COMORBIDITIES 1,8 
538 
LOCAL EXCISION AND REMOVAL OF INTERNAL FIXATION DEVICES EXCEPT HIP AND FEMUR 
WITHOUT CC (added 10-1-03) 1,7 
014 
INTRA CRANIAL HEMORRHAGE AND STROKE WITH INFARCTION (beginning 10-1-02, used to 10-1-
04) 1,6 
410 CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS 1,5 
316 RENAL FAILURE 1,5 
395 RED BLOOD CELL DISORDERS AGE >17 1,5 
247 SIGNS & SYMPTOMS OF MUSCULOSKELETAL SYSTEM & CONNECTIVE TISSUE 1,4 
243 MEDICAL BACK PROBLEMS 1,3 
544 MAJOR JOINT REPLACEMENT OR REATTACHMENT OF LOWER EXTREMITY (added 10-1-05) 1,3 
239 PATHOLOGICAL FRACTURES & MUSCULOSKELETAL & CONNECTIVE TISSUE MALIGNANCY 1,3 
576 SEPTICEMIA W MECHANICAL VENTILATOR W/0 96+ HOURS AGE >17 (added 10-1-06) 1,2 
462 REHABILITATION 1,1 
241 CONNECTIVE TISSUE DISORDERS WITHOUT COMPLICATIONS, COMORBIDITIES 1,1 
240 CONNECTIVE TISSUE DISORDERS WITH COMPLICATIONS, COMORBIDITIES 1,0 
244 BONE DISEASES & SPECIFIC ARTHROPATHIES WITH COMPLICATIONS, COMORBIDITIES 1,0 
234 
OTHER MUSCULOSKELETAL SYSTEM & CONNECTIVE TISSUE OPERATING ROOM PROCEDURES 
WITHOUT COMPLICATIONS, COMORBIDITIES 1,0 
202 CIRRHOSIS & ALCOHOLIC HEPATITIS 1,0 
524 TRANSIENT ISCHEMIA (added 10-1-02) 1,0 
467 OTHER FACTORS INFLUENCING HEALTH STATUS 0,9 
039 LENS PROCEDURES WITH OR WITHOUT VITRECTOMY 0,8 
296 
NUTRITIONAL & MISCELLANEOUS METABOLIC DISORDERS AGE >17 WITH COMPLICATIONS, 
COMORBIDITIES 0,7 
183 
ESOPHAGITIS, GASTROENTERITIS, & MISCELLANEOUS DIGESTIVE DISORDERS AGE >17 WITHOUT 
COMPLICATIONS, COMORBIDITIES 0,7 
248 TENDINITIS, MYOSITIS & BURSITIS 0,7 
429 ORGANIC DISTURBANCES & MENTAL RETARDATION 0,6 
182 
ESOPHAGITIS, GASTROENTERITIS, & MISCELLANEOUS DIGESTIVE DISORDERS AGE >17 WITH 
COMPLICATIONS, COMORBIDITIES 0,6 
082 RESPIRATORY NEOPLASMS 0,6 
466 AFTERCARE WITHOUT HISTORY OF MALIGNANCY AS SECONDARY DIAGNOSIS 0,6 
015 
NONSPECIFIC CEREBROVASCULAR AND PRECEREBRAL OCCLUSION WITHOUT INFARCTION 
(beginning 10-1-02) 0,5 
090 SIMPLE PNEUMONIA & PLEURISY AGE >17 WITHOUT COMPLICATIONS, COMORBIDITIES 0,5 
138 CARDIAC ARRHYTHMIA & CONDUCTION DISORDERS WITH COMPLICATIONS, COMORBIDITIES 0,5 
035 OTHER DISORDERS OF NERVOUS SYSTEM WITHOUT COMPLICATION, COMORBIDITIES 0,5 
174 GASTROINTESTINAL HEMORRHAGE WITH COMPLICATIONS, COMORBIDITIES 0,5 
203 MALIGNANCY OF HEPATOBILIARY SYSTEM OR PANCREAS 0,5 
139 CARDIAC ARRHYTHMIA & CONDUCTION DISORDERS WITHOUT COMPLICATIONS, COMORBIDITIES 0,5 
016 NONSPECIFIC CEREBROVASCULAR DISORDERS WITH COMPLICATIONS, COMORBIDITIES 0,5 
134 HYPERTENSION 0,5 
297 
NUTRITIONAL & MISCELLANEOUS METABOLIC DISORDERS AGE >17 WITHOUT COMPLICATIONS, 
COMORBIDITIES 0,5 
144 OTHER CIRCULATORY SYSTEM DIAGNOSES WITH COMPLICATIONS, COMORBIDITIES 0,5 
078 PULMONARY EMBOLISM 0,5 
320 KIDNEY & URINARY TRACT INFECTIONS AGE >17 WITH COMPLICATIONS, COMORBIDITIES 0,5 
430 PSYCHOSES 0,5 
294 DIABETES AGE >35 0,4 
404 LYMPHOMA & NON-ACUTE LEUKEMIA WITHOUT COMPLICATIONS, COMORBIDITIES 0,4 
403 LYMPHOMA & NON-ACUTE LEUKEMIA WITH COMPLICATIONS, COMORBIDITIES 0,4 
017 NONSPECIFIC CEREBROVASCULAR DISORDERS WITHOUT COMPLICATIONS, COMORBIDITIES 0,4 
216 BIOPSIES OF MUSCULOSKELETAL SYSTEM & CONNECTIVE TISSUE 0,4 
207 DISORDERS OF THE BILIARY TRACT WITH COMPLICATIONS, COMORBIDITIES 0,4 
545 REVISION OF HIP OR KNEE REPLACEMENT (added 10-1-05) 0,4 
205 
DISORDERS OF LIVER EXCEPT MALIGNANCY, CIRRHOSIS, ALCOHOLIC HEPATITIS WITH 
COMPLICATIONS, COMORBIDITIES 0,4 
266 
SKIN GRAFT &/OR DEBRIDEMENT EXCEPT FOR SKIN ULCER OR CELLULITIS WITHOUT 
COMPLICATIONS, COMORBIDITIES 0,4 
130 PERIPHERAL, VASCULAR DISORDERS WITH COMPLICATIONS, COMORBIDITIES 0,4 
181 GASTROINTESTINAL OBSTRUCTION WITHOUT COMPLICATIONS, COMORBIDITIES 0,3 
552 OTHER PERMANENT CARDIAC PACEMAKER IMPLANT WITHOUT MCV DIAGNOSIS (added 10-1-05) 0,3 
034 OTHER DISORDERS OF NERVOUS SYSTEM WITH COMPLICATIONS, COMORBIDITIES 0,3 
301 ENDOCRINE DISORDERS WITHOUT COMPLICATIONS, COMORBIDITIES 0,3 
321 KIDNEY & URINARY TRACT INFECTIONS AGE >17 WITHOUT COMPLICATIONS, COMORBIDITIES 0,3 
233 
OTHER MUSCULOSKELETAL SYSTEM & CONNECTIVE TISSUE OPERATING ROOM PROCEDURES WITH 
COMPLICATIONS, COMORBIDITIES 0,3 
180 GASTROINTESTINAL OBSTRUCTION WITH COMPLICATIONS, COMORBIDITIES 0,3 
009 SPINAL DISORDERS & INJURIES 0,3 
042 INTRAOCULAR PROCEDURES EXCEPT RETINA, IRIS & LENS 0,3 
079 RESPIRATORY INFECTIONS & INFLAMMATIONS AGE >17 WITH COMPLICATIONS, COMORBIDITIES 0,3 
230 LOCAL EXCISION & REMOVAL OF INTERNAL FIXATION DEVICES OF HIP & FEMUR 0,3 
208 DISORDERS OF THE BILIARY TRACT WITHOUT COMPLICATIONS, COMORBIDITIES 0,3 
131 PERIPHERAL VASCULAR DISORDERS WITHOUT COMPLICATIONS, COMORBIDITIES 0,3 
085 PLEURAL EFFUSION WITH COMPLICATIONS, COMORBIDITIES 0,3 
125 
CIRCULATORY DISORDERS EXCEPT ACUTE MYOCARDIAL INFARCTION, WITH CARDIAC CATHETER 
WITHOUT COMPLEX DIAGNOSES 0,3 
172 DIGESTIVE MALIGNANCY WITH COMPLICATIONS, COMORBIDITIES 0,3 
132 ATHEROSCLEROSIS WITH COMPLICATIONS, COMORBIDITIES 0,3 
463 SIGNS & SYMPTOMS WITH COMPLICATIONS, COMORBIDITIES 0,3 
121 
CIRCULATORY DISORDERS WITH ACUTE MYOCARDIAL INFARCTION & MAJOR COMPLICATION, 
DISCHARGED ALIVE (beginning 10-1-97) 0,3 
162 
INGUINAL & FEMORAL HERNIA PROCEDURES AGE >17 WITHOUT COMPLICATIONS, 
COMORBIDITIES 0,3 
145 OTHER CIRCULATORY SYSTEM DIAGNOSES WITHOUT COMPLICATIONS, COMORBIDITIES 0,3 
271 SKIN ULCERS 0,3 
311 TRANSURETHRAL PROCEDURES WITHOUT COMPLICATIONS, COMORBIDITIES 0,3 
143 CHEST PAIN 0,3 
141 SYNCOPE & COLLAPSE WITH COMPLICATIONS, COMORBIDITIES 0,2 
470 UNGROUPABLE 0,2 
142 SYNCOPE & COLLAPSE WITHOUT COMPLICATIONS, COMORBIDITIES 0,2 
122 
CIRCULATORY DISORDERS WITH ACUTE MYOCARDIAL INFARCTION WITHOUT MAJOR 
COMPLICATION, DISCHARGED ALIVE (beginning 10-1-97) 0,2 
423 OTHER INFECTIOUS & PARASITIC DISEASES DIAGNOSES 0,2 
566 RESPIRATORY SYSTEM DIAGNOSIS WITH VENTILATOR SUPPORT <96 HRS (added 10-1-06) 0,2 
175 GASTROINTESTINAL HEMORRHAGE WITHOUT COMPLICATIONS, COMORBIDITIES 0,2 
246 NON-SPECIFIC ARTHROPATHIES 0,2 
189 OTHER DIGESTIVE SYSTEM DIAGNOSES AGE >17 WITHOUT COMPLICATIONS, COMORBIDITIES 0,2 
140 ANGINA PECTORIS 0,2 
204 DISORDERS OF PANCREAS EXCEPT MALIGNANCY 0,2 
231 LOCAL EXCISION & REMOVAL OF INTERNAL FIXATION DEVICES (NO HIP & FEMUR) 0,2 
029 TRAUMATIC STUPOR & COMA, COMA <1 HR AGE >17 WITHOUT COMPLICATIONS, COMORBIDITIES 0,2 
479 OTHER VASCULAR PROCEDURES WITHOUT COMPLICATIONS, CORMORBIDITIES 0,2 
300 ENDOCRINE DISORDERS WITH COMPLICATIONS, COMORBIDITIES 0,2 
019 CRANIAL & PERIPHERAL NERVE DISORDERS WITHOUT COMPLICATIONS, COMORBIDITIES 0,2 
572 MAJOR GASTROINTESTINAL DISORDERS AND PERITONEAL INFECTIONS (added 10-1-06) 0,2 
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